Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


VAD Use Beyond Sickest Patient Population Expected Soon, Experts Agree

This article was originally published in The Gray Sheet

Executive Summary

Ventricular assist technology for patients healthier than those targeted in the pivotal REMATCH trial will be available within the next three years, Mehmet Oz, Columbia University College of Physicians and Surgeons, predicted on March 17

You may also be interested in...

Thoratec HeartMate A Good Choice For The Very Sick Despite Risks – Panel

Thoratec's HeartMate VE left-ventricular assist system (LVAS) should be made available to end-stage heart failure patients ineligible for a transplant, even though 94% of patients treated with the LVAS in clinical trials experienced a serious adverse event, FDA's Circulatory System Devices Panel agreed

World Heart Novacor LVAS Transplant Alternative Trial Enrollment At 28

World Heart has enrolled 28 out of 40 patients to be evaluated in the feasibility phase of its INTrEPID trial for its Novacor left ventricular assist system as an alternative-to-transplant destination therapy

Early Revascularization Aids Heart Attack Patients With Cardiogenic Shock

Early revascularization via angioplasty or bypass surgery significantly increases the six-month survival rate of acute myocardial infarction patients with cardiogenic shock, according to a National Heart, Lung and Blood Institute study.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts